A Phase 3 interventional study of GTP regimen in Refractory, Recurrence and Hemophagocytic Lymphohistiocytosis, sponsored by Beijing Friendship Hospital. Not yet recruiting. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2023-09-14.
Sponsored by Beijing Friendship Hospital · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Lymphohistiocytosis, Hemophagocytic by Beijing Friendship Hospital — 7 open to participants now, 7 under way, 3 of them phase 3. Lymphohistiocytosis, Hemophagocytic · Beijing Friendship Hospital.
Among the 21 studies in Lymphohistiocytosis, Hemophagocytic by Beijing Friendship Hospital, this one is the 16th largest by planned enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2023, is one of 9 in phase 3, and was the 18th registered.
111 studies on the registry are indexed under Lymphohistiocytosis, Hemophagocytic; 41 are open to participants now.
Browse Lymphohistiocytosis, Hemophagocytic studies →7 of the 21 studies in Lymphohistiocytosis, Hemophagocytic by Beijing Friendship Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Friendship Hospital · Sites in China
Ages 14–70
Beijing Friendship Hospital · Sites in China
Ages 18+
Beijing Friendship Hospital · Sites in China
Ages up to 65
Beijing Friendship Hospital · Sites in China
Ages 18+
Beijing Friendship Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 26 Lymphohistiocytosis, Hemophagocytic studies recruiting now, 14 (54%) set no upper age limit and 8 (31%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.
This study: 1 Month and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 11
First in 2015; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 30 across 75 interventional studies indexed under Lymphohistiocytosis, Hemophagocytic.
Median enrollment 30 across the 17 interventional studies, 60 across the 4 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing Friendship Hospital is the lead sponsor of 217 studies on the registry; 94 are open to participants now.
1 of the studies in Lymphohistiocytosis, Hemophagocytic by Beijing Friendship Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06131489Beijing Friendship HospitalSegmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Lymphohistiocytosis, Hemophagocytic by Beijing Friendship Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn about efficacy and safety of GTP regimen in refractory/recurrent hemophagocytic lymphohistiocytosis. The main questions it aims to answer are:
Refractory/recurrent hemophagocytic lymphohistiocytosis will be treated with emapalumab combined with teniposide and methylprednisolone. Observed the overall response rate and side effects.
111 studies on the registry are indexed under Lymphohistiocytosis, Hemophagocytic; 41 are open to participants now.
This study's planned enrollment of 15 is below the median of 30 across 75 interventional studies indexed under Lymphohistiocytosis, Hemophagocytic.
Browse Lymphohistiocytosis, Hemophagocytic studies →Beijing Friendship Hospital is the lead sponsor of 217 studies on the registry; 94 are open to participants now.
Compared within Lymphohistiocytosis, Hemophagocytic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The investigators assessed the presence of /recurrent HLH disease. Patients must meet one of the following criteria assessed by the investigator:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
R/R HLH patients treated with GTP regimen
Drug: GTP regimen
Refractory/recurrent hemophagocytic lymphohistiocytosis patients will be treated with GTP regimen (Emapalumab+Teniposide+Methylprednisolone)
ORR
Overall remission rate
Time frame: 1 year
No study locations are listed for this record.
Start is estimated for Sep 2023; primary completion for Sep 2024, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lymphohistiocytosis, Hemophagocytic →